Is there role for aortic valve balloon valvuloplasty in modern era?

    Authors

    Keywords

    aortic stenosis, balloon valvuloplasty, heart failure

    DOI

    https://doi.org/10.15836/ccar2019.95

    Full Text

    Aim . To investigate early outcomes after balloon aortic valve valvuloplasty (BAV) performed as palliative procedure in patients with decompensated unstable end-stage aortic stenosis (AS). Patients and Methods . A retrospective observational study was conducted in University Hospital Centre Zagreb. It included all patients who underwent lifesaving BAV, and had no options for surgical or transcatheter aortic valve replacement at the time, between 2015 and 2018. Clinical and echocardiographic characteristics before and after BAV procedure were recorded. Results . Study included 29 patients, mean age 80.2 (51-92) years, 65.5% women. Mean logistic Euroscore II was 24.1±21.1% and STS score 16.9±14.5%. Comorbidities included: coronary artery disease (48.28%), diabetes mellitus (31.4%), chronic renal insufficiency (58.6%), peripheral artery disease (17.2%) and atrial fibrillation (55.2%). All patients were dependent on parenteral diuretics and 24.14% on parenteral inotropic support. Echocardiographic parameter before and after BAV are presented in table 1 . There was significant increase in indexed aortic valve area and decrease in pulmonary artery systolic pressure in overall population. There was no significant change in severity of aortic insufficiency. In-hospital mortality was 20.1% (N=6). Periprocedural complications included: 1 (3.4%) myocardial infarction, 1 (3.4%) major bleeding, 1 (3.4%) acute kidney injury and 2 (6.9%) vascular access complications. All other patients have been successfully weaned of parenteral therapy within 4 days and discharged. Conclusion . BAV represents palliative treatment option in critically ill hemodynamically unstable patients with end-stage AS, who are not candidates for valve replacement. ( 1 ) BAV provides clinical improvement due to increase AVA and decrease in PAPs, with acceptable mortality and complications rate.

    Cardiologia Croatica
    Back to search

    Is there role for aortic valve balloon valvuloplasty in modern era?

    Extended Abstract
    Issue3-4
    Published
    Pages95
    PDF via DOIhttps://doi.org/10.15836/ccar2019.95
    aortic stenosis
    balloon valvuloplasty
    heart failure

    Authors

    Zvonimir Ostojić*ORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Vlatka Rešković LukšićORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Marija ManceORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Blanka Glavaš KonjaORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Martina Lovrić BenčićORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Maja StrozziORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Joško BulumORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia
    Jadranka Šeparović HanževačkiORCIDUniversity Hospital Centre Zagreb, Zagreb, Croatia

    Full Text

    Aim . To investigate early outcomes after balloon aortic valve valvuloplasty (BAV) performed as palliative procedure in patients with decompensated unstable end-stage aortic stenosis (AS). Patients and Methods . A retrospective observational study was conducted in University Hospital Centre Zagreb. It included all patients who underwent lifesaving BAV, and had no options for surgical or transcatheter aortic valve replacement at the time, between 2015 and 2018. Clinical and echocardiographic characteristics before and after BAV procedure were recorded. Results . Study included 29 patients, mean age 80.2 (51-92) years, 65.5% women. Mean logistic Euroscore II was 24.1±21.1% and STS score 16.9±14.5%. Comorbidities included: coronary artery disease (48.28%), diabetes mellitus (31.4%), chronic renal insufficiency (58.6%), peripheral artery disease (17.2%) and atrial fibrillation (55.2%). All patients were dependent on parenteral diuretics and 24.14% on parenteral inotropic support. Echocardiographic parameter before and after BAV are presented in table 1 . There was significant increase in indexed aortic valve area and decrease in pulmonary artery systolic pressure in overall population. There was no significant change in severity of aortic insufficiency. In-hospital mortality was 20.1% (N=6). Periprocedural complications included: 1 (3.4%) myocardial infarction, 1 (3.4%) major bleeding, 1 (3.4%) acute kidney injury and 2 (6.9%) vascular access complications. All other patients have been successfully weaned of parenteral therapy within 4 days and discharged. Conclusion . BAV represents palliative treatment option in critically ill hemodynamically unstable patients with end-stage AS, who are not candidates for valve replacement. ( 1 ) BAV provides clinical improvement due to increase AVA and decrease in PAPs, with acceptable mortality and complications rate.